Physical Activity in Pediatric Onset Multiple Sclerosis: Validating a Questionnaire for Clinical Practice and Research

Abstract Background Knowledge regarding physical activity (PA) and its benefits in pediatric onset multiple sclerosis (POMS) is growing and suggests high levels of inactivity. The utility of a validated screening tool for clinical settings is unknown. This study evaluated the Godin Leisure-Time Exer...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2016-11, Vol.10, p.26-29
Main Authors: Kinnett-Hopkins, Dominique, Grover, Stephanie A, Yeh, E. Ann, Motl, Robert W
Format: Article
Language:English
Subjects:
Accelerometry
Adolescent
Age of Onset
Child
Disability Evaluation
Exercise - physiology
Female
Humans
Male
Measurement
Multiple sclerosis
Multiple Sclerosis - physiopathology
Neurology
Pediatric
Physical activity
Surveys and Questionnaires
Validity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Knowledge regarding physical activity (PA) and its benefits in pediatric onset multiple sclerosis (POMS) is growing and suggests high levels of inactivity. The utility of a validated screening tool for clinical settings is unknown. This study evaluated the Godin Leisure-Time Exercise Questionnaire (GLTEQ) as a measure of PA in POMS. Methods POMS patients (n=27) and healthy controls (n=45) wore an accelerometer over a 7-day period and then completed the GLTEQ. Results The GLTEQ captured expected group differences in PA for vigorous, moderate, and moderate-to-vigorous physical activity (MVPA), confirmed by accelerometry. There was a large, positive correlation between GLTEQ and accelerometry scores for vigorous PA in POMS ( r =0.736, p =0.001), and a nearly significant and moderate, positive correlation between MVPA scores ( r =0.319, p =.053). Conclusion We provide evidence that supports the validity of GLTEQ scores as measures of vigorous and MVPA in POMS. Researchers and clinicians might adopt this scale for measuring PA.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2016.08.010